Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals reports news on a commercial-stage biotechnology business focused on hematologic disorders and cancer. Company updates commonly cover sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), along with contract revenue from collaborations and quarterly operating results.
Recurring developments also include clinical and regulatory updates for Rigel's pipeline, including R289 in lower-risk MDS, published clinical data involving GAVRETO, licensing and collaboration activity, board appointments, equity inducement grants and other governance matters tied to its Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Rigel Pharmaceuticals (Nasdaq: RIGL) will announce its first quarter 2023 financial results after market close on May 2, 2023. Following the results release, a live conference call will take place at 4:30 p.m. ET to discuss the outcomes and provide business updates. Interested participants can join the call at 877-407-3088 domestically or 201-389-0927 internationally, or access the webcast via the Rigel website. The archived recording will be available for 90 days post-call. Rigel is focused on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced on April 6, 2023, the granting of 108,600 stock options to three non-executive employees as part of its Inducement Plan. This award is intended to incentivize employees entering employment with Rigel, aligning with NASDAQ Listing Rule 5635(c)(4). The options will vest over four years, with a one-year cliff before any options can be exercised. This move is aimed at enhancing employee retention and motivation within the company. Rigel, based in South San Francisco, focuses on developing innovative therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (RIGL) reported its financial results for Q4 2022, with total revenues of $51.3 million, including $21.9 million from TAVALISSE and $0.9 million from REZLIDHIA. The launch of REZLIDHIA, approved in December 2022, is progressing well, aided by its inclusion in NCCN Guidelines for AML. Rigel also received $20 million from Kissei due to TAVALISSE's approval in Japan. Despite a net income of $1.4 million in Q4 2022, Rigel faced increased total expenses of $49.2 million. For the full year, total revenues reached $120.2 million but resulted in a net loss of $58.6 million.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will release its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. Following the report, Rigel's senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the call by dialing a provided number or through the company's website. Rigel focuses on developing novel small molecule drugs for hematologic disorders and cancer.